Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (US FDA) to market Canagliflozin tablets, 100 mg and 300 mg.

Canagliflozin Tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The drug will be manufactured at the group's formulation manufacturing facility at Moraiya. Canagliflozin Tablets had annual sales of $660 million in the US.